Newly-Published Study Confirms Stretta to be Valuable GERD Treatment - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Newly-Published Study Confirms Stretta to be Valuable GERD Treatment Radiofrequency (RF) Therapy Fills Gap Between Medications and Surgery


Newly-Published Study Confirms Stretta to be Valuable GERD Treatment

Radiofrequency (RF) Therapy Fills Gap Between Medications and Surgery

PR Newswire

NORWALK, Conn., July 15, 2014 /PRNewswire/ -- A newly published peer-reviewed paper concludes that Stretta therapy is a safe, effective and durable treatment for gastro esophageal reflux disease (GERD). The paper states that Stretta addresses a significant unmet need where patients receive inadequate control from PPI therapy and find surgery an undesirable option. The paper was authored by George Triadafilopoulos, MD, Clinical Professor of Medicine at Stanford University School of Medicine and was published in the World Journal of Gastroenterology .

Stretta therapy delivers low power, low temperature radiofrequency energy to remodel the valve known as the lower esophageal
               sphincter (LES) at the junction of the esophagus and the stomach. Stretta reduces or eliminates regurgitation of stomach contents
               by improving muscle tone and reducing random openings of the LES that are known to cause GERD. Stretta treatment results in
               elimination or significant reductions of GERD symptoms and medication use, and significant improvement in patient quality
               of life.

Dr. Triadafilopoulos states, "Today, more than ever, clinicians will benefit from the addition of Stretta to the treatment armamentarium for their GERD patients." The comprehensive review examines the more than 35 studies published on the procedure, including a recent 10-year follow up study, and concludes that Stretta is a highly valuable middle treatment option between PPI's and surgery.

Other conclusions reached:

  • Stretta treatment does not result in any tissue destruction, nor does it create scar tissue
  • Symptom control is consistent among Stretta patients who were previously PPI dependent or poorly controlled by PPI
  • Functional improvements occur post-Stretta, including improved acid sensitivity and decreased tissue compliance
  • Stretta is "exceedingly safe, durable and reproducible"

GERD is the most frequent outpatient diagnosis in the United States. Although most patients are treated with proton pump inhibitors (PPIs), up to 40 percent of patients have incomplete control of reflux symptoms on PPIs.  Stretta is a non-surgical treatment, and involves the delivery of radiofrequency energy to the muscle of the lower esophageal sphincter and gastric cardia. Stretta doesn't alter the anatomy or implant any foreign material and does not preclude further steps with more invasive procedures if indicated. According to the author, Stretta is the least expensive alternative to medical therapy.

ABOUT STRETTA®

Stretta Therapy is a non-surgical treatment for GERD that is an effective option for patients who do not respond well to medications. Recently, Stretta has been the subject of multiple studies, including eight and 10-year follow-up, and has received the strongest grade recommendation from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

ABOUT MEDERI®

Mederi Therapeutics manufactures Stretta and Secca – innovative medical devices that deliver RF energy to treat digestive diseases. Mederi therapies are available worldwide. Mederi is located in Norwalk, CT.

For more information visit www.stretta-therapy.com.

Contact: Julia Brannan
julia@pascalecommunications.com
(908) 464-2470

Photo - http://photos.prnewswire.com/prnh/20130211/NY56794

SOURCE Mederi Therapeutics Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here